Biden Admin Finalizes Rule That Requires Insurers To Submit Data On Drug Costs, Rebates

The Biden administration has issued an interim final rule that requires private insurers to report prescription drug costs to the federal government. The interim rule, which also includes a request for comment, is the latest in a series of regulations implementing provisions of the No Surprises Act and the Consolidated Appropriations Act of 2021. Insurers ...

Read More

Cap On Drug Price Hikes For Privately Insured Sparks Battle

Workers and families with private health insurance would reap savings on prescription drugs from a little-noticed provision in President Joe Biden’s sweeping social agenda bill. It’s meant to break the cycle of annual price increases for widely used medicines. That provision would require drug companies to pay rebates to Medicare if they increase prices above the rate of ...

Read More

CDC Expands Eligibility For Covid-19 Booster Shots To All Adults

An expert committee that advises the Centers for Disease Control and Prevention on vaccines voted 11-to-0 on Friday to recommend Covid-19 booster shot eligibility be thrown open to all adults 18 and older. The Advisory Committee on Immunization Practices also recommended, by the same vote, that the CDC lower the age for adults who should ...

Read More

Americans Can Wait Many Weeks To See A Therapist. California Law Aims To Fix That

When Greta Christina fell into a deep depression five years ago, she called up her therapist in San Francisco — someone she’d had a great connection with when she needed therapy in the past. And she was delighted to find out that he was now “in network” with her insurance company, meaning she wouldn’t have ...

Read More

Avalere: Providers Face 40% Hit To Part B Reimbursements Under Dem Drug Price Reforms

Providers could face a 40% cut on average to their Medicare Part B drug reimbursements under legislation that gives Medicare the power to negotiate a small amount of drug prices in Parts B and D, a new analysis finds. The analysis, released Thursday by consulting firm Avalere, examines the effect of a drug pricing negotiation ...

Read More

No Sanctions Over Deficiencies At California Virus Test Lab

California’s new coronavirus testing laboratory won’t face sanctions for what state officials had called “significant deficiencies” that a whistleblower said threatened the accuracy of its results, authorities said Monday. The Valencia Branch Laboratory was found to have problems with training and record-keeping but authorities couldn’t substantiate reports stemming from a whistleblower that the lab destroyed ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square